KPWS
GRCE

Kestra Private Wealth Services’s Grace Therapeutics GRCE Stock Holding History

Kestra Private Wealth Services’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.2K Buy
23,000
+10,000
+77% +$27.7K ﹤0.01% 1765
2026
Q1 		$60.2K Buy
+13,000
New +$51K ﹤0.01% 1709

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Kestra Private Wealth Services's GRCE Position: Q2 2026 in Review

Kestra Private Wealth Services increased its Grace Therapeutics (GRCE) stake by 77% in Q2 2026, buying an estimated $27.7K and bringing the position to 23,000 shares worth $52.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1765.

Kestra Private Wealth Services first reported a position in GRCE in Q1 2026 and has held it in 2 quarters since. The position peaked at $60.2K in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Kestra Private Wealth Services held 23,000 shares of Grace Therapeutics worth $52.2K as of Q2 2026.
  • Kestra Private Wealth Services bought 10,000 Grace Therapeutics shares in Q2 2026, an estimated $27.7K.
  • Grace Therapeutics made up ﹤0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1765 holding.
  • Kestra Private Wealth Services first reported a position in Grace Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Kestra Private Wealth Services's Grace Therapeutics position peaked at $60.2K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.